Peavine Capital’s AbbVie ABBV Stock Holding History

Peavine Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,676	Closed	-$272K	–	12
2022 Q1	$272K	Hold	1,676	–	–	0.05%	13
2021 Q4	$227K	Buy	+1,676	New	+$198K	0.04%	17
2018 Q4	–	Sell	-21,600	Closed	-$2.04M	–	19
2018 Q3	$2.04M	Hold	21,600	–	–	0.94%	5
2018 Q2	$2M	Hold	21,600	–	–	0.98%	5
2018 Q1	$2.04M	Hold	21,600	–	–	1.05%	5
2017 Q4	$2.09M	Hold	21,600	–	–	1.06%	5
2017 Q3	$1.92M	Hold	21,600	–	–	1.04%	5
2017 Q2	$1.57M	Hold	21,600	–	–	0.89%	5
2017 Q1	$1.41M	Hold	21,600	–	–	0.84%	5
2016 Q4	$1.35M	Sell	21,600 -200	-0.9%	-$12.2K	0.81%	5
2016 Q3	$1.38M	Hold	21,800	–	–	0.67%	5
2016 Q2	$1.35M	Hold	21,800	–	–	0.62%	5
2016 Q1	$1.25M	Buy	21,800 +200	+0.9%	+$11.1K	0.6%	5
2015 Q4	$1.28M	Hold	21,600	–	–	0.65%	5
2015 Q3	$1.18M	Hold	21,600	–	–	0.66%	6
2015 Q2	$1.45M	Hold	21,600	–	–	0.98%	6
2015 Q1	$1.26M	Sell	21,600 -9	-0%	-$544	0.8%	7
2014 Q4	$1.41M	Buy	+21,609	New	+$1.36M	0.91%	7

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Peavine Capital's ABBV Position: Q2 2022 in Review

Peavine Capital sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,676 shares — an estimated $272K sold.

Peavine Capital first reported a position in ABBV in Q4 2014 and held it in 18 quarters. The position peaked at $2.09M in Q4 2017. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Peavine Capital reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Peavine Capital sold 1,676 AbbVie shares in Q2 2022, an estimated $272K.
Peavine Capital first reported a position in AbbVie in Q4 2014 and held it in 18 quarters.
Peavine Capital's AbbVie position peaked at $2.09M in Q4 2017.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Peavine Capital's 13F filing for Q2 2022, filed 22 Jul 2022.